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Summary
Multiple sclerosis is increasingly being recognized as a
neurodegenerative disease that is triggered by in¯am-
matory attack of the CNS. As yet there is no satisfac-
tory treatment. Using experimental allergic encephalo-
myelitis (EAE), an animal model of multiple sclerosis,
we demonstrate that the cannabinoid system is neuro-
protective during EAE. Mice de®cient in the cannabi-
noid receptor CB1 tolerate in¯ammatory and excito-
toxic insults poorly and develop substantial neurodegen-
eration following immune attack in EAE. In addition,
exogenous CB1 agonists can provide signi®cant neuro-
protection from the consequences of in¯ammatory CNS
disease in an experimental allergic uveitis model.
Therefore, in addition to symptom management, canna-
bis may also slow the neurodegenerative processes that
ultimately lead to chronic disability in multiple sclerosis
and probably other diseases.
Keywords: cannabinoids; excitotoxicity; experimental allergic encephalomyelitis; multiple sclerosis; neuroprotection
Abbreviations: 2-AG = 2-arachidonoyl glycerol; CB = cannabinoid receptor; CREAE = chronic relapsing experimental
allergic encephalomyelitis; EAE = experimental allergic encephalomyelitis; EAU = experimental allergic uveitis; ELISA =
enzyme-linked immunosorbent assay; i.p. = intraperitoneal; IRBP = interphotoreceptor retinoid binding protein; NMDA =
N-methyl-D-aspartate; D9-THC = tetrahydrocannabinol
Introduction
Multiple sclerosis is a chronic disease of the CNS, where
autoimmunity is thought to drive the development of
in¯ammatory lesions that induce the primary demyelination,
which results in the inhibition of normal neurotransmission
(Compston and Coles, 2002). However, the observation that
disability often continues to worsen despite immunotherapy,
which reduces blood±brain barrier dysfunction and relapse
rate (Coles et al., 1999; SPECTRIMS Study Group, 2001;
Wiendl and Hohlfeld, 2002) underscores that neurodegen-
erative changes are of major importance in disease progres-
sion (Barnes et al., 1991; Ferguson et al., 1997; Trapp et al.,
1998; Coles et al., 1999). This correlates with gross atrophy
of the CNS, axonal loss and the accumulation of permanent
disability (Bjartmar et al., 2000; Compston and Coles, 2002).
Axonal pathology is an early feature of multiple sclerosis
lesions and is initially associated with in¯ammation (De
Stefano et al., 2001; Filippi et al., 2003); likewise, axonal
damage is a feature in experimental allergic encephalomye-
litis (EAE), an autoimmune model of multiple sclerosis
(Baker et al., 1990; Wujek et al., 2002). During multiple
sclerosis and EAE, destruction of myelin results in the
redistribution and aberrant expression of axonal ion channels,
and demyelinated axons are particularly sensitive to the
damaging effects of free-radicals and glutamate excitotoxi-
city, which may additionally contribute to chronic neurode-
generation in CNS autoimmune disease (Foster et al., 1980;
Black et al., 2000; Pitt et al., 2000; Smith et al., 2000, 2001;
Werner et al., 2001; Lo et al., 2002; Kapoor et al., 2003).
Therapeutic strategies in multiple sclerosis have concentrated
on immunomodulation (Wiendl and Hohl®eld, 2002). There
is an urgent need for agents that can inhibit progressive
multiple sclerosis.
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 Cannabis contains many compounds but it has been found
that the major psychoactive ingredient is D9-tetrahydrocan-
nabinol (D9-THC) (Mechoulam and Gaoni, 1967). D9-THC
mediates the majority of its activities through stimulation of
cannabinoid receptors (CB), notably CB1, which are
expressed throughout the CNS (Matsuda et al., 1990;
Howlett et al., 2002). Following the discovery of the
receptors, fatty acid endogenous ligands, such as anandamide
and 2-arachidonoyl glycerol (2-AG), and a degradation
system including a re-uptake mechanism and hydrolytic
enzymes have been identi®ed (Devane et al., 1992; Deutsch
and Chin, 1993; Mechoulam et al., 1995; Dinh et al., 2002).
The cannabinoid system functions to regulate synaptic
neurotransmission (Kreitzer and Regehr, 2001; Wilson and
Nicoll, 2001) and tonically controls clinical signs such as
spasticity and tremor that develop in chronic EAE (Baker
et al., 2000, 2001). This provides objective evidence to
support the claims of multiple sclerosis patients that cannabis
may have a bene®t in symptom management (Consroe et al.,
1997), a claim further supported by some recent clinical trials
of medical cannabis extracts (Killestein et al., 2002; Robson
et al., 2002; Vaney et al., 2002). There is in vitro evidence
that cannabinoids can also regulate glutamate release, oxidant
free radicals and calcium in¯uxes (Twitchell et al., 1997;
Hampson et al., 1998; Kreitzer and Regehr, 2001; Howlett
et al., 2002), which, in excess, can cause neuronal death in
neuroin¯ammatory disease (Pitt et al., 2000; Smith et al.,
2000; Kapoor et al., 2003). The lack of speci®city of all
available cannabinoid reagents (Howlett et al., 2002) and the
potential presence of additional CB-like receptors (Di Marzo
et al., 2000; Breivogel et al., 2001; Monory et al., 2002)
means that gene-deleted transgenic mice (Ledent et al., 1999;
Zimmer et al., 1999) provide powerful tools to de®nitively
investigate the potential role of the cannabinoid system in
neuroprotection.
Material and methods
Animals
Biozzi ABH and CB1 gene (Cnr1)-de®cient mice were from
stock bred at the Institute of Neurology. They were fed
RM-1(E) diet and water ad libitum. Congenic (N5)
ABH.Cnr1 ±/± ±/+ and +/+ were generated from
CD1.Cnr1±/± knockout mice (Ledent et al., 1999) and
screened as described previously (Brooks et al., 2002).
B10.RIII mice were purchased from Harlan Olac, Oxford,
UK. All experiments were ethically performed according to
the UK Animals (Scienti®c Procedures) Act (1984), under the
control of the UK Government, Home Of®ce.
Chemicals
The cannabinoid receptor agonists R(+)-WIN55,212 and
CP55,940 were purchased from Tocris (Bristol, UK). N-
methyl-D-aspartate (NMDA) and the NMDA receptor
antagonist MK-801 were obtained from Sigma (Poole,
UK). The CB1 selective antagonist rimonabant
(SR141617A; Rinaldi-Carmona et al., 1994) and D9-
THC were from the National Institute for Drugs and
Abuse (NIDA) drug supply program. These were dis-
solved in ethanol : cremophor : PBS (1 : 1 : 18) and
0.1±0.2 ml was injected intraperitoneally (i.p.) daily.
Induction of chronic relapsing EAE (CREAE)
Mice were injected subcutaneously in the ¯ank on day 0 and 7
with 1 mg mouse spinal cord homogenate in complete
Freund's adjuvant [60 mg Mycobacterium tuberculosis
H37Ra, Mycobacterium butyricum (4 : 1) per injection] on
day 0 and 7 (Baker et al., 1990). Clinical disease was assessed
daily and scored: 0 = normal, 1 = limp tail, 2 = impaired
righting re¯ex, 3 = paresis of hindlimbs, 4 = complete
paralysis of hindlimbs and 5 = moribund/death (O'Neill et al.,
1992). The activity of animals was monitored over 5 min in a
27 3 27 cm open-®eld activity chamber (Brooks et al., 2002).
Tissues were either snap-frozen or formaldehyde-®xed for
immunohistology (Baker et al., 1990; Ahmed et al., 2002),
western blotting for caspase activity (Ahmed et al., 2002) and
enzyme-linked immunosorbent assay (ELISA) detection of
CNS proteins.
Table 1 CB1-de®cient mice are susceptible to the development of EAE
Strain No.
EAE/total
Clinical score
(6 SEM)
Day of onset
(6 SD)
ABH (wild type) 15/15 4.0 6 0.1 14.7 6 1.0
ABH.Cnr1+/+ (wild type homozygous) 6/6 4.0 6 0.0 16.3 6 1.8
ABH.Cnr1+/± (heterozygous) 9/9 4.2 6 0.2 15.4 6 1.0
ABH.Cnr1±/± (knockout) 15/15 4.1 6 0.1 16.3 6 1.8
The results represent the number of animals within a group that developed clinical EAE, the mean
maximal clinical score 6 SEM that developed during acute phase EAE (up to day 24 post-inoculation)
and the mean day of onset 6 SD of clinical EAE (score >0.5) The disease incidence, onset and severity
of congenic mice was comparable (P > 0.05) to that found in wild-type ABH mice, as assessed using the
Mann±Whitney U-test.
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 Neuro®lament ELISA
Whole spinal cords were homogenized on ice by trituration
and sonication in 500 ml of barbitone buffer [11 mM
barbital, 63 mM sodium barbital, 1.2 mM EDTA (Sigma)]
containing a protease inhibitor cocktail and 4 mM EGTA.
Lipids were extracted from the sample by adding di-
isopropyl-ether (Sigma) at 1 : 5000 and centrifuging for 5
min at 20 000 g. The supernatant was frozen and stored in
aliquots at ±70°C, and the total protein was measured using
the standard Lowry method. Ninety-six-well microtitre
plates (Maxisorp; Nunc, Rochester, NY, USA) were coated
overnight at 4°C with the SMI35 coat monoclonal antibody
(SMI35; Sternberger Monoclonals Inc., Lutherville, MD,
USA) against neuro®lament heavy chain diluted in 0.05 M
sodium carbonate (pH 9.6). This was followed by a wash
step with barbitone buffer containing 5 mM EDTA, 1%
bovine serum albumin and 0.05% Tween-20 (Sigma). Non-
speci®c protein binding was blocked by incubation with
1% bovine serum albumin in barbitone buffer for 1 h at
room temperature, followed by a wash with wash buffer as
above. Spinal cord homogenates were serially diluted to
1 : 10 000 in barbitone buffer containing 5 mM EDTA,
and incubated at room temperature for 2 h. After washing,
a rabbit polyclonal anti-neuro®lament H antibody (N-4142;
Sigma), diluted 1 : 1000, was incubated at room tempera-
ture for 1 h. Following another wash, horseradish
Fig. 1 Cannabinoids limit accumulation of disability in EAE. CREAE was actively induced in wild-type ABH or CB1 gene (Cnr1)-
de®cient, congenic ABH mice with mouse spinal cord homogenate in complete Freund's adjuvant on day 0 and 7. (A) The mean 6 SEM
daily clinical scores (post-induction) demonstrate that CB1 knockout mice (®lled circles) show poor recovery from paralysis compared
with wild-type mice (open diamonds). (B) Movement activity of normal and animals with EAE in remission after one or four paralytic
disease episodes were measured in an activity chamber over 5 min. The results represent the individual data points (solid circles) and box
plot (25±75% percentile) with 5±95% percentiles range of activity wild-type (open box) and CB1 knockout (shaded box) mice.
Cannabinoid-mediated neuroprotection Page 3 of 12
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 peroxidase-conjugated anti-rabbit immunoglobulin diluted
1 : 1000 was incubated for 1 h at room temperature. The
tetramethylbenzidine chromogenic reagent (R & D Systems
Europe, Minneapolis, MN, USA) was used, signal devel-
opment stopped using 1 M phosphoric acid, and the plate
read at 450 nm, with a reference reading at 620 nm. The
antigen concentration for each sample was calculated from
an internal standard curve ranging from 0 to 250 ng/ml
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 (high-performance liquid chromatography-puri®ed bovine
neuro®lament H; Af®niti Bioreagents, Golden, Colorado,
USA). All samples were analysed in duplicate.
Induction of experimental allergic uveitis (EAU)
B10.RIII mice were injected subcutaneously with 25 mg
interphotoreceptor retinoid binding protein (IRBP151±181)
peptide in complete Freund's adjuvant (as used in EAE
experiments) on day 0 and 7, disease was assessed
histologically, by haematoxylin and eosin-stained 5 mm
paraf®n wax sections, for the level of in®ltration (score 0±6)
and structural damage (score 0±5), as described previously
(Hankey et al., 2001).
Glutamate excitotoxcity
NMDA-induced Ca2+ in¯ux
Cerebellar neurons obtained from 6-day-old wild-type
ABH.Cnr1+/+ and CB1 knockout mice were cultured for
9 days in poly-D-lysine coverslips as described previously
(Evans and Pocock, 1999). At 36 h and 6 days, 10 mM
cytosine arabinoside was added to inhibit non-neuronal
proliferation (Evans and Pocock, 1999). Cells were loaded
with 5 mM of the ¯uorescent Ca2+ indicator dye fura-2
acetoxymethyl ester (Calbiochem, Nottingham, UK), prior
to ionotropic glutamate receptor stimulation with 100 mM
NMDA and subsequent inhibition with the NMDA receptor
antagonist, 10 mM MK-801. This concentration of MK-801
is required to give maximal block of imaged NMDA-
induced Ca2+ in¯uxes in cerebellar neurons (Pocock and
Nicholls, 1998). The CB1 receptor agonist CP55,940 (0.01±
5 mM) was added 5 min before imaging commenced and
was present throughout the experiment. A 12-bit digital
camera acquired images and the output visualized with a
Life Science Resources Merlin Imaging system, version
1.8630 (Perkin Elmer Life Science, Cambridge, UK). Data
were analysed by calculating the 340/380 nm ¯uorescence
ratios with time.
Kainic acid induced lesion
Mice were deeply anaesthetized with halothane and stereo-
tactically injected unilaterally (bregma 2.5 mm, medial-
lateral 1.7 mm and dorsoventral 1.6 mm) with 1.5 nmol of
kainic acid in 30 ml of 0.9% saline over 30 s; the injection
needle was retained for 1 min to prevent re¯ux of ¯uid (Chen
and Strickland, 1997).
Statistical analysis
Non-parametric data were assessed using the Mann±Whitney
U-test with Minitab software (Coventry, UK), parametric
data were assessed using t-tests with Sigmastat software. The
group score represents the maximal clinical grade developed
by all animals within the group.
Fig. 2 Cannabinoids mediate neuroprotection in experimental allergic encephalomyelitis. CREAE was actively induced in wild-type ABH
or CB1 gene (Cnr1)-de®cient, congenic ABH mice with mouse spinal cord homogenate in complete Freund's adjuvant on day 0 and 7,
and disease progression in wild-type mice is associated with axonal damage and loss. (A) Spinal cord neuro®lament levels from tissue
homogenates from wild-type (open boxes) and CB1 knockout (shaded boxes) mice were measured by ELISA from normal and animals
with EAE in remission after one or four paralytic disease episodes during EAE. The results represent the mean 6 SEM neuro®lament
levels (n = 6±8 per group). **P < 0.01, ***P < 0.001 compared with respective normal controls. (B±E) Axonal damage was re¯ected
histologically. Bielshowsky silver stain of paraf®n 5 mm wax sections of lumbar spinal cord in (B) normal and (C) chronic EAE after four
attacks, demonstrating few surviving axons (arrows) and note the loss of axons in the dorsal horn. Neuro®lament-speci®c
immunocytochemistry of the spinal cord from a CB1 knockout mouse (D) before and (E) after a single paralytic episode of EAE. Note the
many transactions of the white matter axons. (F) Caspase-1 and -3 levels were assessed using western analysis and caspase-3 levels are
signi®cantly (P < 0.001) elevated in CB1 knockout mice (shaded boxes) during acute EAE compared with wild type (open boxes)
(Student's t-test; n = 6 per group).
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 Results
Development of chronic paresis in EAE is
associated with accumulation of axonal loss
Following actively, spinal cord homogenate-induced
CREAE, ABH mice develop a relapsing±remitting disease
progression of distinct paralytic disease episodes followed by
remission with an increasing residual de®cit (Baker et al.,
1990, 2000). Although histological axonal damage occurs in
the initial acute phase of CREAE in ABH mice, this becomes
much more evident, particularly in the spinal cord, following
the development of relapsing disease (Baker et al., 1990;
Ahmed et al., 2002). Whilst EAE has classically been
assessed using a subjectively scored scale of paralysis
(Table 1; Fig. 1A) (Baker et al., 1990; Smith et al., 2000;
Lo et al., 2002), accumulating residual de®cit could be
quantitatively demonstrated through assessment of mobility
of remission animals in an open-®eld activity chamber
(Fig. 1B). Whilst ABH mice remitted to exhibit more
immobility after one episode of paralysis (P < 0.001; clinical
score 0.5), movement activity was further reduced (P <
0.001) after three to four episodes (clinical grade 2.5±3),
where animals had chronically developed residual hind limb
paresis upon recovery from relapsing paralytic episodes
(Fig. 1B). This immobility was associated with accumulating
axonal loss, which could be quantitatively assessed using a
neuro®lament ELISA (Fig. 2A), and demonstrated histologi-
cally (Fig. 2B and C).
The cannabinoid system regulates EAE-induced
neurodegeneration
Wild-type (ABH) and congenic wild-type homozygous
(ABH.Cnr1+/+), heterozygotes (ABH.Cnr1+/±) and CB1-
de®cient (ABH.Cnr1±/±) mice developed EAE with compar-
able incidence, severity and onset (Table 1). There was,
however, an increased frequency (>5%) of EAE-induced
mortality in CB1-de®cient mice and also in heterozygotes,
which have reduced CB1 expression (Selley et al., 2001).
However, most strikingly CB1-de®cient mice exhibited
signi®cantly (P < 0.05) more immobility and residual paresis
(Fig. 1) and axonal pathology (Fig. 2A and D±F) than wild-
type mice following recovery after the ®rst paralytic episode.
These animals relapse and accumulate more de®cits that
rapidly reach an acceptable severity limit, including the
development of permanent hindlimb paralysis. Consistent
with the enhanced neurodegeneration after a single attack,
spasticity (Baker et al., 2000) developed early in
ABH.Cnr1±/± mice, which in wild-type ABH mice usually
only occurs after three to four attacks (Baker et al., 2000).
Injection of wild-type mice with the CB1 antagonist (twice
daily with 5 mg/kg rimonabant i.p. from onset; n = 8) induced
greater mortality than usually occurs (<5%). However, using
clinical signs of remission, the level of neurodegeneration
was not as consistent as that found in CB1-de®cient animals
(data not shown). Although multiple pathways contribute to
axonal damage in EAE, the ®nal effector mechanism in
neuronal death is probably toxic ion in¯uxes (Ca2+) and
caspase-3-mediated apoptosis (Ahmed et al., 2002), and
consistent with this, ABH.Cnr1±/± mice exhibited signi®-
cantly (P < 0.001) elevated levels of active caspase-3 during
acute-phase EAE compared with wild-type ABH.Cnr1±/±
mice, although levels of caspase-1 activity were comparable
(Fig. 2F). Caspase-3 could be detected immunocytochemi-
cally in dying axons and these axons demonstrated many
transections, which is a feature of multiple sclerosis (Trapp
et al., 1998) (Fig. 2D and E). Therefore, neurodegeneration is
clearly elevated in CB1-de®cient mice following in¯amma-
tory insults, suggesting that CB1 agonism should have
neuroprotective potential in CB1-wild-type animals, in add-
ition to controlling neurological symptoms such as tremor
and spasticity (Baker et al., 2000).
Exogenous CB1 agonism is neuroprotective in
in¯ammatory CNS disease
In CREAE in ABH mice, the neurological de®cit accumulates
slowly over a number of months and multi-focal lesions can
occur anywhere along the neuroaxis (Baker et al., 1990),
complicating assessment and treatment of neurodegeneration,
especially as limited quantities of D9-THC were available for
study. In contrast, neurodegeneration is restricted to a focal
site and develops rapidly in EAU. Following sensitization of
B10.RIII mice with IRBP153±180 peptide, the neuroretina is
almost completely destroyed within 14±16 days (Hankey
et al., 2001) (Fig. 3A±E), again associated with caspase-3-
induced neuronal pathology (not shown). CB1 receptor
agonism with either R(+)-WIN-55,212-2 (Figs 3C and 4A),
at doses that demonstrated no immunosuppressive effect in
EAE (vehicle: n = 9/9, clinical score 3.3 6 0.4, day of onset
17.6 6 1.2; compared with 5 mg/kg i.p. R(+)-WIN 55,212-2
from day 10±22, n = 7/8, clinical score 3.4 6 0.5, day of onset
17.3 6 1.8), and D9-THC signi®cantly inhibited photorecep-
tor damage, without any apparent inhibition of in¯ammatory
in®ltrate (Figs 3E and 4B). Therefore, CB1 agonism can
mediate neuroprotection during in¯ammatory insults.
Cannabinoids regulate/inhibit glutamate
excitotoxicity
Although immunosuppression, shown by a reduction in the
degree of in®ltrate, was not evident following treatment with
R(+)-WIN-55, 212±2 or D9-THC (Fig. 3) shortly before
expression of disease, D9-THC has been reported to have
immunosuppressive effects (Lyman et al., 1989; Wirguin
et al., 1994), which could in¯uence neurodegenerative
potential. As glutamate excitotoxicity has been implicated
in neuronal damage in this and other EAE models (Achiron
et al., 2000; Pitt et al., 2000; Smith et al., 2000), glutamate-
induced excitotoxicity was examined in vitro and following
CNS injection of kainic acid in vivo to examine neuro-
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 protective potential in the absence of a compounding
immunomodulation. Following in vitro stimulation of
NMDA receptors there was a marked (cerebellar) neuronal
Ca2+ in¯ux, which was more pronounced in CB1-de®cient
mice than in controls, suggesting that the cannabinoid system
exhibits tonic control of this response (Fig. 5A). In addition,
the NMDA receptor antagonist (MK-801) was slower at
reducing Ca2+ to basal levels in CB1-de®cient mice compared
with ABH.Cnr1+/+ wild type, suggesting Ca2+ dysregulation
in the absence of CB1 receptors had occurred. Exogenous
CB1 agonism by CP55,940 inhibited this NMDA-induced
cytosolic Ca2+ in¯ux in wild-type animals, maximally at 1
mM using these culture conditions, but was relatively
ineffective in CB1-knockout mice, suggesting that post-
synaptic control of NMDA-receptor activation is lost in CB1-
de®cient mice (Fig. 5A). The injection of kainic acid (>0.15
nM) into CB1-de®cient mice induced seizures and caused
mortality, usually within 10 min post-injection, which did not
occur in wild-type ABH and ABH congenic wild-type
(Fig. 5B) mice (P < 0.01), despite using 50-fold higher
doses of kainic acid. This elevated mortality was also evident
in CD1.Cnr1±/± mice (Fig. 5B), and therefore CB1 receptors
are also clearly regulating ionotropic glutamate receptor
activity (Fig. 5), which has been implicated in neural
exocitoxicity.
Discussion
Neurological disability in multiple sclerosis correlates with
spinal cord axonal loss (~50±70% in paralysed multiple
sclerosis patients) and reduced N-acetyl aspartate (NAA)
levels in chronic multiple sclerosis patients (Bjartmar et al.,
2000). This study provides the ®rst and de®nitive evidence
that the cannabinoid system controls the development of
neurodegeneration, which occurs as a result of in¯ammatory
insult of the CNS. This provides a novel avenue for
neuroprotection in multiple sclerosis and other neurodegen-
erative diseases.
In diseases such as EAE and multiple sclerosis, it is
unlikely that there is a single route to neurodegenerative
events, and these may change during the disease course. The
Fig. 3 Cannabinoids limit neurodegeneration of the retina in EAU.
(A) Paraf®n-wax section of normal retina in a B10.RIII mouse.
Mice were injected with IRBP153±180 peptide in Freund's adjuvant
and vehicle (B, D) or cannabinoid (C, E) was injected daily from
day 8 onwards. Retinas were assessed histologically on either (B,
C) day 15 or (D, E) day 21 post-inoculation following treatment
with either (C) 5 mg/kg i.p. R(+)-WIN55,212 or (E) 20 mg/kg i.p.
D9-THC.
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 clinical outcome will be determined by the rate that these
accumulate and how the genetic background of the individual
enables them to adapt to the insult. Whilst axonal loss occurs
very early in the course of multiple sclerosis (Filippi et al.,
2003), it can remain clinically silent for some time, and
irreversible neurological disability appears to develop when a
threshold (15±30% in mice) of axonal loss is reached and
compensatory CNS resources are exhausted (Confavreux
et al., 2000; Wujek et al., 2002). In this model, marginal,
statistically non-signi®cant axonal loss occurred after the
initial neurological attack, assessed here using a novel,
relatively rapid neuro®lament ELISA and by changes in NAA
levels (Preece et al., 1994). Once chronic paresis was evident
there was signi®cant axonal loss (~40%) as shown here by
ELISA and also by magnetic resonance spectroscopy of
spinal cord NAA levels (R. A. Page, H. G. Parkes, D. Baker,
G. Giovannoni and C. A. Davie, unpublished observations).
However, most interestingly, CB1-de®cient mice accumu-
lated signi®cant axonal loss (~36%) even after a single acute
episode, indicating that the presence of CB1 was mediating a
degree of neuroprotection during autoimmune attack.
Surprisingly, analysis of spinal cord axonal content indicated
that apparently normal, CB1-de®cient ABH mice have fewer
spinal nerves than wild-type animals (P < 0.001), which may
be re¯ective of CB1 involvement in neural plasticity during
development (Kim and Thayer, 2001), or there could be
inherent neurodegeneration in these animals. This requires
further study.
In EAE and, at least initially, in multiple sclerosis axonal
damage occurs at least concordantly with in¯ammation
(Ferguson et al., 1997; Trapp et al., 1998), which produces
many potentially damaging elements such as cytokines and
oxidative stress (Koprowski et al., 1993; Werner et al., 2001;
Lock et al., 2002). Ionotropic glutamate receptor systems can
also signal damaging mechanisms, at the blood±brain barrier
and within the neural microenvironment, in EAE and multiple
sclerosis (Bolton and Paul, 1997; Achiron et al., 2000; Pitt
et al., 2000; Smith et al., 2000; Kalkers et al., 2002). As
shown here, cannabinoids can tonically regulate NMDA
glutamate receptor activity in vitro and support the in vivo
observation that CB1 regulates NMDA-induced and ischae-
mic excitotoxicity (Nagayama et al., 1999; Parmentier-
Batteur et al., 2002). We also show de®nitively that CB1
receptor activity regulates kainate glutamate receptor activity
in vivo. Cannabinoids also have anti-oxidant properties that
could further limit damaging events during in¯ammation
(Hampson et al., 1998; Howlett et al., 2002). In addition,
cellular changes such as neural and oligodendrocyte death
and gliosis will change the CNS microenvironment, for
example through redistribution of ion channels on demyeli-
nated nerves (Foster et al., 1980; Black et al., 2000), loss of
trophic support and the formation of compensatory neural
pathways, which may contribute to excitotoxic stress and
induce further degeneration. This could amplify as the disease
progresses, possibly largely independent of in¯ammation
(Compston and Coles, 2002), and may have similarities to
nerve destruction in other neurodegenerative conditions, such
as Huntington's chorea, Alzheimer's disease and amyo-
trophic lateral sclerosis, where nerve loss accumulates
slowly. The cannabinoid system acts as a regulator of many
different neurotransmitters and ion (K+ and particularly Ca2+)
channels (Henry and Chavkin, 1995; Twitchell et al., 1997;
Howlett et al., 2002) and appears to be particularly important
when CNS homeostasis is in imbalance, as occurs in disease
(Baker et al., 2000). Therefore, CB1 can act at many levels
within the death cascade, which will ultimately lead to toxic
ion in¯uxes, cell metabolic failure and activation of death
effector molecules, such as caspase-3 (Ahmed et al., 2002).
This would be consistent with the rapid neurodegeneration
that accumulates in CB1-de®cient mice. Thisalso implicates a
role for endocannabinoids in neuroprotection. The nature of
Fig. 4 Cannabinoids mediate neuroprotection in EAU. Following
active induction of EAU in B10.RIII mice with IRBP153±180
peptide in complete Freund's adjuvant, eyes were processed for
routine wax histology and the level of in®ltration (scale 0±5) and
structural damage (scale 0±6) assessed. Animals received daily
injections of (A) 5 mg/kg i.p. R(+)-WIN55,212 or (B) 20 mg/kg
i.p. D9-THC, dissolved in ethanol : cremophor : PBS (1 : 1 : 18),
from day 8 onwards. The data represent the results on days 15 and
21 post-inoculation, respectively. The number of animals with
EAU per group is indicated. *P < 0.05, **P < 0.01 compared with
respective control group.
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 the endogenous neuroprotective cannabinoid has yet to be
de®nitively resolved and may involve more than one CB1-
mediated pathway, possibly dependent on the neural circuit
involved. Whilst in head trauma it has been suggested that 2-
AG may mediate neuroprotection (Panikashvili et al., 2001),
in a similar study anandamide, not 2-AG, was shown to be
active (Hansen et al., 2001). However, as both anandamide
and 2-AG are elevated in chronic EAE lesions (Baker et al.,
2001) both may participate in endogenous neuroprotective
mechanisms. This will be elucidated once suitable agents to
dissect these pathways become available.
Previous studies in non-demyelinating EAE models have
demonstrated that high-dose D9-THC, often administered
during the induction process, has clinical disease ameliorat-
ing effects, due to prevention of in®ltrate reaching the CNS
(Lyman et al., 1989; Wirguin et al., 1994). Furthermore, D9-
THC had no effect on the clinical course, which in Lewis rats
is usually naturally self-limiting, when treatment was initi-
Fig. 5 Cannabinoids inhibit glutamate-induced excitotoxicity. (A) Lack of CB1 receptors leads to loss of
regulation of NMDA-induced calcium in¯ux. Cerebellar neurons from wild-type and CB1 knockout mice
were loaded with the ¯uorescence Ca2+ indicator dye fura-2 prior to ionotropic glutamate receptor
stimulation. Each trace is the mean somatic response of 40 individual neurons measured by single-cell
¯uorescence imaging. The NMDA receptor agonist, NMDA (100 mM), was added at the arrow and the
NMDA receptor antagonist, MK-801, was added at the arrowhead. Where indicated, the CB1 receptor
agonist CP55,940 (1 mM) was added 5 min before imaging commenced and was present throughout the
experiment. (B) Kainate-induced excitotoxicity in vivo. Halothane anaesthetized animals (n = 5 per
group) were intracerebrally injected with 15±0.15 nmol of kainic acid. Rapid (1±10 min) mortality (open
blocks) developed in ABH.Cnr1±/± mice compared with the survival (0 out of 5 mortality; shaded
blocks) that occurred in wild type (ABH.Cnr1+/+). Seizures consistent with glutamate excitotoxicity were
evident. CB1 knockout animals died within 1±3 min of injection, whereas heterozygotes typically showed
adverse effects 5±10 min after injection. Doses lower than the maximal survival dose for each strain were
not tested.
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 ated at disease onset (Lyman et al., 1989). Acute phase
paralysis in most rodent EAE models is rapidly reversed and
can occur largely independent of any demyelination and
axonal loss, and more probably re¯ects conduction block
(Wujek et al., 2002). Therefore, inhibition of acute phase
paralysis (Lyman et al., 1989) may re¯ect inhibition of the
immune process that leads to damage in addition to neural
effects. Indeed, CB agonists have recently been reported to
have immunomodulatory effects in a viral model of multiple
sclerosis (Arevalo-Martin et al., 2003; Croxford and Miller,
2003). Without the use of tissue-speci®c CB1 conditional
knockouts (Marsicano et al., 2002), it is probably not possible
to completely exclude some in¯uence of cannabinoid inhib-
ition of the immune response in the neurodegenerative
process. However, in the context of multiple sclerosis, both
would be of bene®t for inhibition of disease.
The results of this study are important because they suggest
that in addition to symptom management, cannabinoids offer
the potential to slow the progression of a disease that as yet
has no satisfactory treatment. Therefore, if trials are extended
to monitor the long-term effects of cannabis use on symptom
management, they should be designed to monitor neuronal
loss and progression. If CB1 agonism can be applied whilst
limiting the unwanted psychoactive potential, such as through
enhancement of endocannabinoid levels (Baker et al., 2001),
this may provide a new therapeutic route in multiple sclerosis
and could be combined with therapies that target the
immunological elements of disease. In neurodegenerative
diseases including multiple sclerosis, signs appear once
signi®cant damage has already accumulated, slowing the
degenerative process early following diagnosis may help
improve quality of life for many more years.
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